Background Whether the early use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors
have cardioprotective effects following acute myocardial infarction is unknown. Thus, we …

Aim Mortality from acute myocardial infarction (AMI) has declined, increasing the pool of
survivors at risk of later development of heart failure (HF). However, coronary reperfusion …

Aims Patients with heart failure (HF) and history of myocardial infarction (MI) face a higher
risk of disease progression and clinical events. Whether sodium–glucose cotransporter 2 …

Heart failure with preserved ejection fraction (HFpEF) represents a multifaceted syndrome
related to complex pathologic mechanisms. Sacubitril/valsartan (Sac/val) has demonstrated …

Heart failure and myocardial infarction, global health concerns, stem from limited cardiac
regeneration post-injury. Myocardial infarction, typically caused by coronary artery blockage …

Background: Although several studies suggest that heparins prevent arrhythmias caused by
acute myocardial infarction (AMI), the molecular mechanisms involved remain unclear. To …

Abstract Ethnopharmacological relevance Optimized New Shengmai Powder (ONSMP) is a
sophisticated traditional Chinese medicinal formula renowned for bolstering vital energy …

James et al1 report the results of the DAPA-MI (DAPAagliflozin in patients without diabetes
mellitus with acute Myocardial Infarction) trial, which studied the efficacy and safety of early …

Background. Sleep apnea (SA) is a common breathing disorder characterized by repetitive
upper airway narrowing and closure. Although SA has been demonstrated to be an …

Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …